These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38483360)

  • 21. Host-to-graft Propagation of α-synuclein in a Mouse Model of Parkinson's Disease: Intranigral Versus Intrastriatal Transplantation.
    Patrigeon M; Brot S; Bonnet ML; Belnoue L; Gaillard A
    Transplantation; 2023 Aug; 107(8):e201-e212. PubMed ID: 36944598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.
    George S; Rey NL; Tyson T; Esquibel C; Meyerdirk L; Schulz E; Pierce S; Burmeister AR; Madaj Z; Steiner JA; Escobar Galvis ML; Brundin L; Brundin P
    Mol Neurodegener; 2019 Aug; 14(1):34. PubMed ID: 31419995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
    Harrison IF; Smith AD; Dexter DT
    Neurosci Lett; 2018 Feb; 666():48-57. PubMed ID: 29273397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
    Thome AD; Standaert DG; Harms AS
    PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of alpha-synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo.
    Lee EJ; Aguirre-Padilla DH; Fomenko A; Pawar G; Kapadia M; George J; Lozano AM; Hamani C; Kalia LV; Kalia SK
    Brain Stimul; 2024; 17(2):166-175. PubMed ID: 38342364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.
    Thakur P; Breger LS; Lundblad M; Wan OW; Mattsson B; Luk KC; Lee VMY; Trojanowski JQ; Björklund A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8284-E8293. PubMed ID: 28900002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AAV2/DJ-mediated alpha-synuclein overexpression in the rat substantia nigra as early stage model of Parkinson's disease.
    von Hövel FF; Rumpel R; Ratzka A; Schreiner D; Grothe C
    Cell Tissue Res; 2019 Oct; 378(1):1-14. PubMed ID: 30989398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
    Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
    J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.
    Ledonne A; Massaro Cenere M; Paldino E; D'Angelo V; D'Addario SL; Casadei N; Nobili A; Berretta N; Fusco FR; Ventura R; Sancesario G; Guatteo E; Mercuri NB
    Mov Disord; 2023 Feb; 38(2):256-266. PubMed ID: 36350188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
    Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
    PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
    Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
    Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuronal haemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein.
    Santulli C; Bon C; De Cecco E; Codrich M; Narkiewicz J; Parisse P; Perissinotto F; Santoro C; Persichetti F; Legname G; Espinoza S; Gustincich S
    Cell Death Dis; 2022 Dec; 13(12):1048. PubMed ID: 36526614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vanillin Mitigates the MPTP-Induced α-Synucleinopathy in a Mouse Model of Parkinson's Disease: Insights into the Involvement of Wnt/β-Catenin Signaling.
    Rani L; Mondal AC
    J Integr Neurosci; 2024 Sep; 23(9):175. PubMed ID: 39344237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.
    Jakova E; Moutaoufik MT; Lee JS; Babu M; Cayabyab FS
    Transl Neurodegener; 2022 Feb; 11(1):9. PubMed ID: 35139916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priming mesenchymal stem cells with α-synuclein enhances neuroprotective properties through induction of autophagy in Parkinsonian models.
    Shin JY; Kim DY; Lee J; Shin YJ; Kim YS; Lee PH
    Stem Cell Res Ther; 2022 Sep; 13(1):483. PubMed ID: 36153562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.